{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T08:22:20Z","timestamp":1795162940907,"version":"4.10.3"},"reference-count":91,"publisher":"Bentham Science Publishers Ltd.","issue":"5","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CRR"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Psoriatic arthritis (PsA) is a heterogeneous inflammatory disease with various joint and\nskin manifestations and multiple associated comorbidities. The management of PsA is important\nnot only in controlling disease activity and preventing subsequent damage but also in improving\nthe quality of life and reducing mortality. Over the years, numerous drugs have been introduced into\nthe therapeutic armamentarium of the disease. While non-steroidal anti-inflammatory drugs (NSAIDs)\nand conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs) have contributed\nto management, it was not until the advent of biologics (and later on targeted synthetic\nDMARDs) that therapy was revolutionized, with the achievement of significantly better clinical\nand radiographic outcomes. Several drugs and treatment approaches are currently being tested in\nclinical trials at different phases. Despite all the success, there are still various challenges and unmet\nneeds in the field of PsA, reflected by difficult-to-treat disease course, secondary failure of\ntherapy, and lack of consensus on accepted treatment withdrawal protocols, among others.\nIn this mini-review, we have discussed the most recent advances in the therapy of psoriatic disease,\nwith a particular focus on phase III studies completed (or ongoing) since 2020. We also mentioned\nthe challenges and unmet needs in our clinical practice, which we expect current and future\nresearch to provide answers to.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0115733971339350240830104424","type":"journal-article","created":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T16:41:28Z","timestamp":1736008888000},"page":"495-504","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Updates on Recent Advances in the Therapy of Adult Psoriatic Disease"],"prefix":"10.2174","volume":"21","author":[{"given":"Fadi","family":"Kharouf","sequence":"first","affiliation":[{"name":"Psoriatic Arthritis Program, University of Toronto, University Health Network, Toronto Western Hospital, Toronto,Ontario, Canada"},{"name":"Krembil-Gladman Psoriatic Arthritis Program, Toronto Western Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna D","family":"Gladman","sequence":"additional","affiliation":[{"name":"Psoriatic Arthritis Program, University of Toronto, University Health Network, Toronto Western Hospital, Toronto,Ontario, Canada"},{"name":"Krembil-Gladman Psoriatic Arthritis Program, Toronto Western Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.7861\/clinmedicine.17-1-65","volume":"17","author":"Coates L.C.","year":"2017","unstructured":"Coates L.C.; Helliwell P.S.; Psoriatic arthritis: state of the art review. Clin Med (Lond)  2017,17(1),65-70","journal-title":"Clin Med (Lond)"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"Coates L.C.","year":"2022","unstructured":"Coates L.C.; Soriano E.R.; Corp N.; Bertheussen H.; Callis Duffin K.; Campanholo C.B.; Chau J.; Eder L.; Fern&#xE1;ndez-&#xC1;vila D.G.; FitzGerald O.; Garg A.; Gladman D.D.; Goel N.; Helliwell P.S.; Husni M.E.; Jadon D.R.; Katz A.; Laheru D.; Latella J.; Leung Y.Y.; Lindsay C.; Lubrano E.; Mazzuoccolo L.D.; Mease P.J.; O\u2019Sullivan D.; Ogdie A.; Olsder W.; Palominos P.E.; Schick L.; Steinkoenig I.; de Wit M.; van der Windt D.A.; Kavanaugh A.; Campanholo C.; Fitzgerald O.; Gladman D.; Helliwell P.; Husni M.E.; Laheru D.; Leung Y-Y.; Lubrano E.; Mazzuoccolo L.D.; Mease P.J.; Ogdie A.; Palominos P.E.; Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol  2022,18(8),465-479","journal-title":"Nat Rev Rheumatol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.rdc.2015.07.008","volume":"41","author":"Husni M.E.","year":"2015","unstructured":"Husni M.E.; Comorbidities in Psoriatic Arthritis. Rheum Dis Clin North Am  2015,41(4),677-698","journal-title":"Rheum Dis Clin North Am"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"Ritchlin C.T.","year":"2017","unstructured":"Ritchlin C.T.; Colbert R.A.; Gladman D.D.; Psoriatic Arthritis. N Engl J Med  2017,376(10),957-970","journal-title":"N Engl J Med"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1586\/1744666X.2014.905741","volume":"10","author":"Eder L.","year":"2014","unstructured":"Eder L.; Gladman D.D.; Predictors for clinical outcome in psoriatic arthritis \u2013 what have we learned from cohort studies? Expert Rev Clin Immunol  2014,10(6),763-770","journal-title":"Expert Rev Clin Immunol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S0950-3579(94)80030-8","volume":"8","author":"Cu&#xE9;llar M.L.","year":"1994","unstructured":"Cu&#xE9;llar M.L.; Citera G.; Espinoza L.R.; Treatment of psoriatic arthritis. Baillieres Clin Rheumatol  1994,8(2),483-498","journal-title":"Baillieres Clin Rheumatol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.semarthrit.2017.02.001","volume":"47","author":"Merola J.F.","year":"2017","unstructured":"Merola J.F.; Lockshin B.; Mody E.A.; Switching biologics in the treatment of psoriatic arthritis. Semin Arthritis Rheum  2017,47(1),29-37","journal-title":"Semin Arthritis Rheum"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1002\/acr.25112","volume":"75","author":"Rida M.A.","year":"2023","unstructured":"Rida M.A.; Lee K.A.; Chandran V.; Cook R.J.; Gladman D.D.; Persistence of biologics in the treatment of psoriatic arthritis: data from a large hospital-based longitudinal cohort. Arthritis Care Res (Hoboken)  2023,75(10),2174-2181","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.rdc.2015.07.006","volume":"41","author":"Barnas J.L.","year":"2015","unstructured":"Barnas J.L.; Ritchlin C.T.; Etiology and pathogenesis of psoriatic arthritis. Rheum Dis Clin North Am  2015,41(4),643-663","journal-title":"Rheum Dis Clin North Am"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"596086","DOI":"10.3389\/fimmu.2020.596086","volume":"11","author":"Vecellio M.","year":"2021","unstructured":"Vecellio M.; Hake V.X.; Davidson C.; Carena M.C.; Wordsworth B.P.; Selmi C.; The IL-17\/IL-23 axis and its genetic contribution to psoriatic arthritis. Front Immunol  2021,11,596086","journal-title":"Front Immunol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"668","DOI":"10.55563\/clinexprheumatol\/e7ayu8","volume":"39","author":"Crispino N.","year":"2021","unstructured":"Crispino N.; Ciccia F.; JAK\/STAT pathway and nociceptive cytokine signalling in rheumatoid arthritis and psoriatic arthritis. Clin Exp Rheumatol  2021,39(3),668-675","journal-title":"Clin Exp Rheumatol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","volume":"80","author":"Traves P.G.","year":"2021","unstructured":"Traves P.G.; Murray B.; Campigotto F.; Galien R.; Meng A.; Di Paolo J.A.; JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann Rheum Dis  2021,80(7),865-875","journal-title":"Ann Rheum Dis"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","volume":"382","author":"McInnes I.B.","year":"2013","unstructured":"McInnes I.B.; Kavanaugh A.; Gottlieb A.B.; Puig L.; Rahman P.; Ritchlin C.; Brodmerkel C.; Li S.; Wang Y.; Mendelsohn A.M.; Doyle M.K.; Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet  2013,382(9894),780-789","journal-title":"Lancet"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"Ritchlin C.","year":"2014","unstructured":"Ritchlin C.; Rahman P.; Kavanaugh A.; McInnes I.B.; Puig L.; Li S.; Wang Y.; Shen Y.K.; Doyle M.K.; Mendelsohn A.M.; Gottlieb A.B.; Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6- month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis  2014,73(6),990-999","journal-title":"Ann Rheum Dis"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","volume":"395","author":"Deodhar A.","year":"2020","unstructured":"Deodhar A.; Helliwell P.S.; Boehncke W.H.; Kollmeier A.P.; Hsia E.C.; Subramanian R.A.; Xu X.L.; Sheng S.; Agarwal P.; Zhou B.; Zhuang Y.; Ritchlin C.T.; Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF&#x3B1; inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet  2020,395(10230),1115-1125","journal-title":"Lancet"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","volume":"395","author":"Mease P.J.","year":"2020","unstructured":"Mease P.J.; Rahman P.; Gottlieb A.B.; Kollmeier A.P.; Hsia E.C.; Xu X.L.; Sheng S.; Agarwal P.; Zhou B.; Zhuang Y.; van der Heijde D.; McInnes I.B.; Guselkumab in biologic- naive patients with active psoriatic arthritis (discover-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet  2020,395(10230),1126-1136","journal-title":"Lancet"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1093\/rheumatology\/keac375","volume":"62","author":"Coates L.C.","year":"2023","unstructured":"Coates L.C.; Ritchlin C.T.; Gossec L.; Helliwell P.S.; Rahman P.; Kollmeier A.P.; Xu X.L.; Shawi M.; Karyekar C.S.; Contr&#xE9; C.; No&#xEB;l W.; Sheng S.; Wang Y.; Xu S.; Mease P.J.; Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis. Rheumatology (Oxford)  2023,62(2),606-616","journal-title":"Rheumatology (Oxford)"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1136\/annrheumdis-2021-220991","volume":"81","author":"Coates L.C.","year":"2022","unstructured":"Coates L.C.; Gossec L.; Theander E.; Bergmans P.; Neuhold M.; Karyekar C.S.; Shawi M.; No&#xEB;l W.; Schett G.; McInnes I.B.; Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS). Ann Rheum Dis  2022,81(3),359-369","journal-title":"Ann Rheum Dis"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13075-023-03125-4","volume":"25","author":"Schett G.","year":"2023","unstructured":"Schett G.; Chen W.; Gao S.; Chakravarty S.D.; Shawi M.; Lavie F.; Zimmermann M.; Sharaf M.; Coates L.C.; Siebert S.; Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study. Arthritis Res Ther  2023,25(1),150","journal-title":"Arthritis Res Ther"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13063-022-06945-y","volume":"24","author":"Ritchlin C.T.","year":"2023","unstructured":"Ritchlin C.T.; Coates L.C.; Mease P.J.; van der Heijde D.; Song J.; Jiang Y.; Shawi M.; Kollmeier A.P.; Rahman P.; The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial. Trials  2023,24(1),22","journal-title":"Trials"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1186\/s13063-022-06589-y","volume":"23","author":"Gladman D.D.","year":"2022","unstructured":"Gladman D.D.; Mease P.J.; Bird P.; Soriano E.R.; Chakravarty S.D.; Shawi M.; Xu S.; Quinn S.T.; Gong C.; Leibowitz E.; Poddubnyy D.; Tam L.S.; Helliwell P.S.; Kavanaugh A.; Deodhar A.; &#xD8;stergaard M.; Baraliakos X.; Efficacy and safety of guselkumab in biologic-na&#xEF;ve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial. Trials  2022,23(1),743","journal-title":"Trials"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s40265-020-01357-1","volume":"80","author":"Blair H.A.","year":"2020","unstructured":"Blair H.A.; Risankizumab: a review in moderate to severe plaque psoriasis. Drugs  2020,80(12),1235-1245","journal-title":"Drugs"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1136\/annrheumdis-2021-221019","volume":"81","author":"Kristensen L.E.","year":"2022","unstructured":"Kristensen L.E.; Keiserman M.; Papp K.; McCasland L.; White D.; Lu W.; Wang Z.; Soliman A.M.; Eldred A.; Barcomb L.; Behrens F.; Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. Ann Rheum Dis  2022,81(2),225-231","journal-title":"Ann Rheum Dis"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/annrheumdis-2021-221048","volume":"81","author":"&#xD6;st&#xF6;r A.","year":"2022","unstructured":"&#xD6;st&#xF6;r A.; Van den Bosch F.; Papp K.; Asnal C.; Blanco R.; Aelion J.; Alperovich G.; Lu W.; Wang Z.; Soliman A.M.; Eldred A.; Barcomb L.; Kivitz A.; Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial. Ann Rheum Dis  2022,81(3),351-358","journal-title":"Ann Rheum Dis"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","volume":"390","author":"Reich K.","year":"2017","unstructured":"Reich K.; Papp K.A.; Blauvelt A.; Tyring S.K.; Sinclair R.; Tha&#xE7;i D.; Nograles K.; Mehta A.; Cichanowitz N.; Li Q.; Liu K.; La Rosa C.; Green S.; Kimball A.B.; Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (resurface 1 and resurface 2): results from two randomised controlled, phase 3 trials. Lancet  2017,390(10091),276-288","journal-title":"Lancet"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1136\/annrheumdis-2020-219014","volume":"80","author":"Mease P.J.","year":"2021","unstructured":"Mease P.J.; Chohan S.; Fructuoso F.J.G.; Luggen M.E.; Rahman P.; Raychaudhuri S.P.; Chou R.C.; Mendelsohn A.M.; Rozzo S.J.; Gottlieb A.; Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study. Ann Rheum Dis  2021,80(9),1147-1157","journal-title":"Ann Rheum Dis"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"ard-2024-225531","DOI":"10.1136\/ard-2024-225531","volume":"83","author":"Gossec L.","year":"2024","unstructured":"Gossec L.; Kerschbaumer A.; Ferreira R.J.O.; Aletaha D.; Baraliakos X.; Bertheussen H.; Boehncke W.H.; Esbensen B.A.; McInnes I.B.; McGonagle D.; Winthrop K.L.; Balanescu A.; Balint P.V.; Burmester G.R.; Ca&#xF1;ete J.D.; Claudepierre P.; Eder L.; Hetland M.L.; Iagnocco A.; Kristensen L.E.; Lories R.; Queiro R.; Mauro D.; Marzo-Ortega H.; Mease P.J.; Nash P.; Wagenaar W.; Savage L.; Schett G.; Shoop-Worrall S.J.W.; Tanaka Y.; Van den Bosch F.E.; van der Helm-van Mil A.; Zabotti A.; van der Heijde D.; Smolen J.S.; EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis  2024,83(6),ard-2024-225531","journal-title":"Ann Rheum Dis"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.semarthrit.2018.05.011","volume":"48","author":"Araujo e.g.","year":"2019","unstructured":"Araujo e.g.; Englbrecht M.; Hoepken S.; Finzel S.; Kampylafka E.; Kleyer A.; Bayat S.; Schoenau V.; Hueber A.; Rech J.; Schett G.; Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study. Semin Arthritis Rheum  2019,48(4),632-637","journal-title":"Semin Arthritis Rheum"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40257-020-00578-0","volume":"22","author":"Yang K.","year":"2021","unstructured":"Yang K.; Oak A.S.W.; Elewski B.E.; Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review. Am J Clin Dermatol  2021,22(2),173-192","journal-title":"Am J Clin Dermatol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"Blauvelt A.","year":"2017","unstructured":"Blauvelt A.; Papp K.A.; Griffiths C.E.M.; Randazzo B.; Wasfi Y.; Shen Y.K.; Li S.; Kimball A.B.; Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator\u2013controlled VOYAGE 1 trial. J Am Acad Dermatol  2017,76(3),405-417","journal-title":"J Am Acad Dermatol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"Reich K.","year":"2017","unstructured":"Reich K.; Armstrong A.W.; Foley P.; Song M.; Wasfi Y.; Randazzo B.; Li S.; Shen Y.K.; Gordon K.B.; Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator\u2013controlled VOYAGE 2 trial. J Am Acad Dermatol  2017,76(3),418-431","journal-title":"J Am Acad Dermatol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","volume":"394","author":"Reich K.","year":"2019","unstructured":"Reich K.; Gooderham M.; Tha&#xE7;i D.; Crowley J.J.; Ryan C.; Krueger J.G.; Tsai T.F.; Flack M.; Gu Y.; Williams D.A.; Thompson E.H.Z.; Paul C.; Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator- controlled phase 3 trial. Lancet  2019,394(10198),576-586","journal-title":"Lancet"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s40265-023-01857-w","volume":"83","author":"Poddubnyy D.","year":"2023","unstructured":"Poddubnyy D.; Managing psoriatic arthritis patients presenting with axial symptoms. Drugs  2023,83(6),497-505","journal-title":"Drugs"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","volume":"77","author":"Baeten D.","year":"2018","unstructured":"Baeten D.; &#xD8;stergaard M.; Wei J.C.C.; Sieper J.; J&#xE4;rvinen P.; Tam L.S.; Salvarani C.; Kim T.H.; Solinger A.; Datsenko Y.; Pamulapati C.; Visvanathan S.; Hall D.B.; Aslanyan S.; Scholl P.; Padula S.J.; Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis  2018,77(9),1295-1302","journal-title":"Ann Rheum Dis"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/art.40728","volume":"71","author":"Deodhar A.","year":"2019","unstructured":"Deodhar A.; Gensler L.S.; Sieper J.; Clark M.; Calderon C.; Wang Y.; Zhou Y.; Leu J.H.; Campbell K.; Sweet K.; Harrison D.D.; Hsia E.C.; van der Heijde D.; Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol  2019,71(2),258-270","journal-title":"Arthritis Rheumatol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1136\/annrheumdis-2015-209068","volume":"75","author":"Kavanaugh A.","year":"2016","unstructured":"Kavanaugh A.; Puig L.; Gottlieb A.B.; Ritchlin C.; You Y.; Li S.; Song M.; Randazzo B.; Rahman P.; McInnes I.B.; Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1\/PSUMMIT-2). Ann Rheum Dis  2016,75(11),1984-1988","journal-title":"Ann Rheum Dis"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"e715","DOI":"10.1016\/S2665-9913(21)00105-3","volume":"3","author":"Mease P.J.","year":"2021","unstructured":"Mease P.J.; Helliwell P.S.; Gladman D.D.; Poddubnyy D.; Baraliakos X.; Chakravarty S.D.; Kollmeier A.P.; Hsia E.C.; Xu X.L.; Sheng S.; Agarwal P.; Zhou B.; Sweet K.; Shawi M.; Karyekar C.S.; Deodhar A.; van der Heijde D.; Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies. Lancet Rheumatol  2021,3(10),e715-e723","journal-title":"Lancet Rheumatol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1136\/annrheumdis-2021-221422","volume":"81","author":"Braun J.","year":"2022","unstructured":"Braun J.; Landew&#xE9; R.B.M.; No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related \u2018physician-reported spondylitis\u2019? Ann Rheum Dis  2022,81(4),466-468","journal-title":"Ann Rheum Dis"},{"key":"ref=39","first-page":"1759720X2110579","volume":"13","author":"Poddubnyy D","year":"2021","unstructured":"Poddubnyy D; Baraliakos X; Van Den Bosch F; Braun J; Coates LC; Chandran V; Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Ther Adv Musculoskelet Dis  2021,13,1759720X2110579","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2147\/PTT.S367744","volume":"12","author":"Ruggiero A.","year":"2022","unstructured":"Ruggiero A.; Potestio L.; Camela E.; Fabbrocini G.; Megna M.; Bimekizumab for the treatment of psoriasis: a review of the current knowledge. Psoriasis (Auckl)  2022,12,127-137","journal-title":"Psoriasis (Auckl)"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","volume":"401","author":"McInnes I.B.","year":"2023","unstructured":"McInnes I.B.; Asahina A.; Coates L.C.; Landew&#xE9; R.; Merola J.F.; Ritchlin C.T.; Tanaka Y.; Gossec L.; Gottlieb A.B.; Warren R.B.; Ink B.; Assudani D.; Bajracharya R.; Shende V.; Coarse J.; Mease P.J.; Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). Lancet  2023,401(10370),25-37","journal-title":"Lancet"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","volume":"401","author":"Merola J.F.","year":"2023","unstructured":"Merola J.F.; Landew&#xE9; R.; McInnes I.B.; Mease P.J.; Ritchlin C.T.; Tanaka Y.; Asahina A.; Behrens F.; Gladman D.D.; Gossec L.; Gottlieb A.B.; Tha&#xE7;i D.; Warren R.B.; Ink B.; Assudani D.; Bajracharya R.; Shende V.; Coarse J.; Coates L.C.; Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-&#x3B1; inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). Lancet  2023,401(10370),38-48","journal-title":"Lancet"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1002\/art.42280","volume":"74","author":"Coates L.C.","year":"2022","unstructured":"Coates L.C.; McInnes I.B.; Merola J.F.; Warren R.B.; Kavanaugh A.; Gottlieb A.B.; Gossec L.; Assudani D.; Bajracharya R.; Coarse J.; Ink B.; Ritchlin C.T.; Safety and efficacy of bimekizumab in patients with active psoriatic arthritis: three-year results from a phase IIb randomized controlled trial and its open-label extension study. Arthritis Rheumatol  2022,74(12),1959-1970","journal-title":"Arthritis Rheumatol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","volume":"79","author":"Mease P.J.","year":"2020","unstructured":"Mease P.J.; Smolen J.S.; Behrens F.; Nash P.; Liu Leage S.; Li L.; Tahir H.; Gooderham M.; Krishnan E.; Liu-Seifert H.; Emery P.; Pillai S.G.; Helliwell P.S.; A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na&#xEF;ve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis  2020,79(1),123-131","journal-title":"Ann Rheum Dis"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","volume":"395","author":"McInnes I.B.","year":"2020","unstructured":"McInnes I.B.; Behrens F.; Mease P.J.; Kavanaugh A.; Ritchlin C.; Nash P.; Masmitja J.G.; Goupille P.; Korotaeva T.; Gottlieb A.B.; Martin R.; Ding K.; Pellet P.; Mpofu S.; Pricop L.; Secukinumab versus adalimumab for treatment of active psoriatic arthritis (Exceed): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet  2020,395(10235),1496-1505","journal-title":"Lancet"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa2102388","volume":"385","author":"Warren R.B.","year":"2021","unstructured":"Warren R.B.; Blauvelt A.; Bagel J.; Papp K.A.; Yamauchi P.; Armstrong A.; Langley R.G.; Vanvoorden V.; De Cuyper D.; Cioffi C.; Peterson L.; Cross N.; Reich K.; Bimekizumab versus Adalimumab in Plaque Psoriasis. N Engl J Med  2021,385(2),130-141","journal-title":"N Engl J Med"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaad.2016.08.008","volume":"76","author":"Blauvelt A.","year":"2017","unstructured":"Blauvelt A.; Reich K.; Tsai T.F.; Tyring S.; Vanaclocha F.; Kingo K.; Ziv M.; Pinter A.; Vender R.; Hugot S.; You R.; Milutinovic M.; Tha&#xE7;i D.; Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. J Am Acad Dermatol  2017,76(1),60-69.e9","journal-title":"J Am Acad Dermatol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1111\/bjd.15666","volume":"177","author":"Reich K.","year":"2017","unstructured":"Reich K.; Pinter A.; Lacour J.P.; Ferrandiz C.; Micali G.; French L.E.; Lomaga M.; Dutronc Y.; Henneges C.; Wilhelm S.; Hartz S.; Paul C.; Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. Br J Dermatol  2017,177(4),1014-1023","journal-title":"Br J Dermatol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","volume":"397","author":"Reich K.","year":"2021","unstructured":"Reich K.; Papp K.A.; Blauvelt A.; Langley R.G.; Armstrong A.; Warren R.B.; Gordon K.B.; Merola J.F.; Okubo Y.; Madden C.; Wang M.; Cioffi C.; Vanvoorden V.; Lebwohl M.; Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet  2021,397(10273),487-498","journal-title":"Lancet"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","volume":"73","author":"Tha&#xE7;i D.","year":"2015","unstructured":"Tha&#xE7;i D.; Blauvelt A.; Reich K.; Tsai T.F.; Vanaclocha F.; Kingo K.; Ziv M.; Pinter A.; Hugot S.; You R.; Milutinovic M.; Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol  2015,73(3),400-409","journal-title":"J Am Acad Dermatol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","volume":"373","author":"Lebwohl M.","year":"2015","unstructured":"Lebwohl M.; Strober B.; Menter A.; Gordon K.; Weglowska J.; Puig L.; Papp K.; Spelman L.; Toth D.; Kerdel F.; Armstrong A.W.; Stingl G.; Kimball A.B.; Bachelez H.; Wu J.J.; Crowley J.; Langley R.G.; Blicharski T.; Paul C.; Lacour J.P.; Tyring S.; Kircik L.; Chimenti S.; Callis Duffin K.; Bagel J.; Koo J.; Aras G.; Li J.; Song W.; Milmont C.E.; Shi Y.; Erondu N.; Klekotka P.; Kotzin B.; Nirula A.; Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med  2015,373(14),1318-1328","journal-title":"N Engl J Med"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa2102383","volume":"385","author":"Reich K.","year":"2021","unstructured":"Reich K.; Warren R.B.; Lebwohl M.; Gooderham M.; Strober B.; Langley R.G.; Paul C.; De Cuyper D.; Vanvoorden V.; Madden C.; Cioffi C.; Peterson L.; Blauvelt A.; Bimekizumab versus Secukinumab in Plaque Psoriasis. N Engl J Med  2021,385(2),142-152","journal-title":"N Engl J Med"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","volume":"394","author":"Reich K.","year":"2019","unstructured":"Reich K.; Armstrong A.W.; Langley R.G.; Flavin S.; Randazzo B.; Li S.; Hsu M.C.; Branigan P.; Blauvelt A.; Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet  2019,394(10201),831-839","journal-title":"Lancet"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/bjd.18851","volume":"182","author":"Blauvelt A.","year":"2020","unstructured":"Blauvelt A.; Papp K.; Gottlieb A.; Jarell A.; Reich K.; Maari C.; Gordon K.B.; Ferris L.K.; Langley R.G.; Tada Y.; Lima R.G.; Elmaraghy H.; Gallo G.; Renda L.; Park S.Y.; Burge R.; Bagel J.; Vender R.; Lomaga M.A.; Delorme I.; Hong C-H.; Langley R.L.; Albrecht L.; Guenther L.; Maari C.; Papp K.; Singh Ohson K.K.; Barber K.; Lynde C.; Gupta A.; Rosoph L.; Gauthier J-S.; Gooderham M.; Wasel N.; Raman M.; Wiseman M.; Greenstein D.; Jarell A.; Moon C.; Clark L.; Jazayeri S.S.; Bukhalo M.; Moore A.; Hamilton T.K.; Gewirtzman A.; Hazan L.; Crowley J.; Teller C.; Zirwas M.; Smith S.R.; Christine Lee M.; Tyring S.; Lee P.; Dhawan S.; Leonardi C.; Jesus A.P-D.; McFalda W.; Frankel E.; Yamauchi P.; Fretzin S.; Serrao R.; Schlesinger T.; Gottlieb S.; Jenkin P.; Gharib R.; Davis S.; Nami N.; Draelos Z.D.; Godwin L.; Owen C.; Landis M.; Abramovits W.; Sanchez-Rivera S.; Van Voorhees A.; Fivenson D.; Kerdel F.; Forman S.B.; Weinberg J.; Gonzalez-Chavez J.; Boyce B.; Stein-Gold L.; Hudson C.; Brown C.; Coggi J.; Feser C.; Forconi R.; Johnson S.; McCune M.; Green L.; Madkan V.; Shipp D.M.; Gordon K.; Waibel J.; Soto-Raices O.; Cather J.; Miller S.; Scott J.; Young D.; Kaffenberger J.; Yokum K.; Zook M.; Blauvelt A.; Truett A.; Schmieder G.; McCracken G.; McElgunn P.; Herrmann J.; Suchniak J.M.; Appel J.; Barranco E.; Lee M.; Bagel J.; Osman L.; Cauthen A.; Sadick N.; De La Torre E.; Taylor K.; Cohen D.; Harris H.H.; Soung J.; Dimitropoulos V.; Miller S.; Barnes C.; Jumean-Haddad R.; Bruce S.; Cheung L.; Guenthner S.; Gaspari A.; Laquer V.; Krell J.M.; Jacobs S.; Nahm W.; Korman N.; Elewski B.; Ferris L.; Duffin K.C.; Pariser D.; Johnson B.; Wallace P.; Travers J.; Fried R.; A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br J Dermatol  2020,182(6),1348-1358","journal-title":"Br J Dermatol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/bjd.19509","volume":"184","author":"Blauvelt A.","year":"2021","unstructured":"Blauvelt A.; Leonardi C.; Elewski B.; Crowley J.J.; Guenther L.C.; Gooderham M.; Langley R.G.; Vender R.; Pinter A.; Griffiths C.E.M.; Tada Y.; Elmaraghy H.; Lima R.G.; Gallo G.; Renda L.; Burge R.; Park S.Y.; Zhu B.; Papp K.; A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Br J Dermatol  2021,184(6),1047-1058","journal-title":"Br J Dermatol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/bjd.19341","volume":"184","author":"Warren R.B.","year":"2021","unstructured":"Warren R.B.; Blauvelt A.; Poulin Y.; Beeck S.; Kelly M.; Wu T.; Geng Z.; Paul C.; Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy\u2013assessor-blinded clinical trial. Br J Dermatol  2021,184(1),50-59","journal-title":"Br J Dermatol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","volume":"82","author":"Ramiro S.","year":"2023","unstructured":"Ramiro S.; Nikiphorou E.; Sepriano A.; Ortolan A.; Webers C.; Baraliakos X.; Landew&#xE9; R.B.M.; Van den Bosch F.E.; Boteva B.; Bremander A.; Carron P.; Ciurea A.; van Gaalen F.A.; G&#xE9;her P.; Gensler L.; Hermann J.; de Hooge M.; Husakova M.; Kiltz U.; L&#xF3;pez-Medina C.; Machado P.M.; Marzo-Ortega H.; Molto A.; Navarro-Comp&#xE1;n V.; Nissen M.J.; Pimentel-Santos F.M.; Poddubnyy D.; Proft F.; Rudwaleit M.; Telkman M.; Zhao S.S.; Ziade N.; van der Heijde D.; ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis  2023,82(1),19-34","journal-title":"Ann Rheum Dis"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1136\/annrheumdis-2020-218808","volume":"80","author":"Baraliakos X.","year":"2021","unstructured":"Baraliakos X.; Gossec L.; Pournara E.; Jeka S.; Mera-Varela A.; D\u2019Angelo S.; Schulz B.; Rissler M.; Nagar K.; Perella C.; Coates L.C.; Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis  2021,80(5),582-590","journal-title":"Ann Rheum Dis"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"1759720X231189005","DOI":"10.1177\/1759720X231189005","volume":"15","author":"Deodhar A","year":"2023","unstructured":"Deodhar A; Gladman D; Bolce R; Sandoval D; Park SY; Leage SL;  The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2. Ther Adv Musculoskelet Dis  2023,15,1759720X231189005","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","volume":"384","author":"McInnes I.B.","year":"2021","unstructured":"McInnes I.B.; Anderson J.K.; Magrey M.; Merola J.F.; Liu Y.; Kishimoto M.; Jeka S.; Pacheco-Tena C.; Wang X.; Chen L.; Zueger P.; Liu J.; Pangan A.L.; Behrens F.; Trial of upadacitinib and adalimumab for psoriatic arthritis. N Engl J Med  2021,384(13),1227-1239","journal-title":"N Engl J Med"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","volume":"80","author":"Mease P.J.","year":"2021","unstructured":"Mease P.J.; Lertratanakul A.; Anderson J.K.; Papp K.; Van den Bosch F.; Tsuji S.; Dokoupilova E.; Keiserman M.; Wang X.; Zhong S.; McCaskill R.M.; Zueger P.; Pangan A.L.; Tillett W.; Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis  2021,80(3),312-320","journal-title":"Ann Rheum Dis"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"e001838","DOI":"10.1136\/rmdopen-2021-001838","volume":"7","author":"McInnes I.B.","year":"2021","unstructured":"McInnes I.B.; Kato K.; Magrey M.; Merola J.F.; Kishimoto M.; Pacheco-Tena C.; Haaland D.; Chen L.; Duan Y.; Zueger P.; Liu J.; Lippe R.; Pangan A.L.; Behrens F.; Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study. RMD Open  2021,7(3),e001838","journal-title":"RMD Open"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","volume":"88","author":"Armstrong A.W.","year":"2023","unstructured":"Armstrong A.W.; Gooderham M.; Warren R.B.; Papp K.A.; Strober B.; Tha&#xE7;i D.; Morita A.; Szepietowski J.C.; Imafuku S.; Colston E.; Throup J.; Kundu S.; Schoenfeld S.; Linaberry M.; Banerjee S.; Blauvelt A.; Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol  2023,88(1),29-39","journal-title":"J Am Acad Dermatol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","volume":"88","author":"Strober B.","year":"2023","unstructured":"Strober B.; Tha&#xE7;i D.; Sofen H.; Kircik L.; Gordon K.B.; Foley P.; Rich P.; Paul C.; Bagel J.; Colston E.; Throup J.; Kundu S.; Sekaran C.; Linaberry M.; Banerjee S.; Papp K.A.; Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol  2023,88(1),40-51","journal-title":"J Am Acad Dermatol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","volume":"81","author":"Mease P.J.","year":"2022","unstructured":"Mease P.J.; Deodhar A.A.; van der Heijde D.; Behrens F.; Kivitz A.J.; Neal J.; Kim J.; Singhal S.; Nowak M.; Banerjee S.; Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis  2022,81(6),815-822","journal-title":"Ann Rheum Dis"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1080\/1744666X.2018.1512404","volume":"14","author":"Berekmeri A.","year":"2018","unstructured":"Berekmeri A.; Mahmood F.; Wittmann M.; Helliwell P.; Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert Rev Clin Immunol  2018,14(9),719-730","journal-title":"Expert Rev Clin Immunol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","volume":"75","author":"Edwards C.J.","year":"2016","unstructured":"Edwards C.J.; Blanco F.J.; Crowley J.; Birbara C.A.; Jaworski J.; Aelion J.; Stevens R.M.; Vessey A.; Zhan X.; Bird P.; Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis  2016,75(6),1065-1073","journal-title":"Ann Rheum Dis"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S0140-6736(12)60642-4","volume":"380","author":"Papp K.","year":"2012","unstructured":"Papp K.; Cather J.C.; Rosoph L.; Sofen H.; Langley R.G.; Matheson R.T.; Hu C.; Day R.M.; Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet  2012,380(9843),738-746","journal-title":"Lancet"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/art.40753","volume":"71","author":"Deodhar A.","year":"2019","unstructured":"Deodhar A.; Poddubnyy D.; Pacheco-Tena C.; Salvarani C.; Lespessailles E.; Rahman P.; J&#xE4;rvinen P.; Sanchez-Burson J.; Gaffney K.; Lee E.B.; Krishnan E.; Santisteban S.; Li X.; Zhao F.; Carlier H.; Reveille J.D.; Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase  randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. Arthritis Rheumatol  2019,71(4),599-611","journal-title":"Arthritis Rheumatol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","volume":"392","author":"van der Heijde D.","year":"2018","unstructured":"van der Heijde D.; Cheng-Chung Wei J.; Dougados M.; Mease P.; Deodhar A.; Maksymowych W.P.; Van den Bosch F.; Sieper J.; Tomita T.; Landew&#xE9; R.; Zhao F.; Krishnan E.; Adams D.H.; Pangallo B.; Carlier H.; Churchill M.; Flint K.; Gladstein G.; Greenwald M.; Howell M.; Ince A.; Kaine J.; Mehta D.; Peters E.; Querubin R.; Reveille J.; Roseff R.; Diegel R.; Thai C.; Bessette L.; Morin F.; Rahman P.; Barrera Rodriguez A.A.; Cons-Molina F.; Duran Barragan S.; Skinner C.; Pacheco Tena C.; Ramos Remus C.; Rizo Rodriguez J.C.; Hong S-J.; Lee Y-A.; Ju J.H.; Kang S.W.; Kim T-H.; Lee C.K.; Lee E.B.; Lee S.H.; Park M-C.; Shin K.; Lee S-H.; Chen H-A.; Chen Y-C.; Hsieh S-C.; Lan J-L.; Dvorak Z.; Moravcova R.; Malcova M.; Taniguchi Y.; Kishimoto M.; Tada K.; Dobashi H.; Inui K.; Ueki Y.; Matsumoto Y.; Koyama Y.; Hatta K.; Atsumi T.; Goto H.; Matsui K.; Takakubo Y.; Neeck G.; Poddubnyy D.; Rubbert-Roth A.; Szymanska M.; Blicharski T.; Dudek A.; Racewicz A.; Wojciechowski R.; van de Sande M.; Griep E.; Nurmohamed M.; Matsievskaya G.; Shmidt E.; Stanislav M.; Yakushin S.; Ershova O.; Rebrov A.; Balazs T.; Cseuz R.; Drescher E.; Poor G.; Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet  2018,392(10163),2441-2451","journal-title":"Lancet"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","volume":"80","author":"Deodhar A.","year":"2021","unstructured":"Deodhar A.; Sliwinska-Stanczyk P.; Xu H.; Baraliakos X.; Gensler L.S.; Fleishaker D.; Wang L.; Wu J.; Menon S.; Wang C.; Dina O.; Fallon L.; Kanik K.S.; van der Heijde D.; Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis  2021,80(8),1004-1013","journal-title":"Ann Rheum Dis"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","volume":"394","author":"van der Heijde D.","year":"2019","unstructured":"van der Heijde D.; Song I.H.; Pangan A.L.; Deodhar A.; van den Bosch F.; Maksymowych W.P.; Kim T.H.; Kishimoto M.; Everding A.; Sui Y.; Wang X.; Chu A.D.; Sieper J.; Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial. Lancet  2019,394(10214),2108-2117","journal-title":"Lancet"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13075-023-03027-5","volume":"25","author":"Baraliakos X.","year":"2023","unstructured":"Baraliakos X.; Ranza R.; &#xD6;st&#xF6;r A.; Ciccia F.; Coates L.C.; Rednic S.; Walsh J.A.; Douglas K.; Gao T.; Kato K.; Song I.H.; Ganz F.; Deodhar A.; Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies. Arthritis Res Ther  2023,25(1),56","journal-title":"Arthritis Res Ther"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"e048647","DOI":"10.1136\/bmjopen-2021-048647","volume":"11","author":"Proft F.","year":"2021","unstructured":"Proft F.; Torgutalp M.; Muche B.; Rios R.V.; Verba M.; Poddubnyy D.; Efficacy of tofacitinib in reduction of inflammation detected on MRI in patients with Psoriatic ArthritiS presenTing with axial involvement (PASTOR): protocol of a randomised, double-blind, placebo-controlled, multicentre trial. BMJ Open  2021,11(11),e048647","journal-title":"BMJ Open"},{"key":"ref=75","first-page":"1089","volume":"7","author":"Hamilton T.K.","year":"2008","unstructured":"Hamilton T.K.; Treatment of psoriatic arthritis and recalcitrant skin disease with combination therapy. J Drugs Dermatol  2008,7(11),1089-1093","journal-title":"J Drugs Dermatol"},{"key":"ref=76","first-page":"394","volume":"18","author":"Rathod D.","year":"2019","unstructured":"Rathod D.; Weinberg J.M.; Yamauchi P.S.; Kircik L.H.; Wollina U.; Lotti T.; Goldust M.; Successful treatment of refractory plaque-type psoriasis and psoriatic arthritis with guselkumab and adalimumab combination therapy: a case report. J Drugs Dermatol  2019,18(4),394-396","journal-title":"J Drugs Dermatol"},{"key":"ref=77","first-page":"1098","volume":"12","author":"Heinecke G.M.","year":"2013","unstructured":"Heinecke G.M.; Luber A.J.; Levitt J.O.; Lebwohl M.G.; Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center. J Drugs Dermatol  2013,12(10),1098-1102","journal-title":"J Drugs Dermatol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.jdcr.2019.08.015","volume":"5","author":"Thibodeaux Q.","year":"2019","unstructured":"Thibodeaux Q.; Ly K.; Reddy V.; Smith M.P.; Liao W.; Dual biologic therapy for recalcitrant psoriasis and psoriatic arthritis. JAAD Case Rep  2019,5(10),928-930","journal-title":"JAAD Case Rep"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3899\/jrheum.110295","volume":"39","author":"Cuchacovich R","year":"2012","unstructured":"Cuchacovich R; Garcia-Valladares I; Espinoza LR; Combination biologic treatment of refractory psoriasis and psoriatic arthritis. J Rheumatol  2012,39(1),187-193","journal-title":"J Rheumatol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1002\/art.20221","volume":"50","author":"Genovese M.C.","year":"2004","unstructured":"Genovese M.C.; Cohen S.; Moreland L.; Lium D.; Robbins S.; Newmark R.; Bekker P.; Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum  2004,50(5),1412-1419","journal-title":"Arthritis Rheum"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1016\/j.semarthrit.2020.01.012","volume":"50","author":"Alharbi S.","year":"2020","unstructured":"Alharbi S.; Ye J.Y.; Lee K.A.; Chandran V.; Cook R.J.; Gladman D.D.; Remission in psoriatic arthritis: Definition and predictors. Semin Arthritis Rheum  2020,50(6),1494-1499","journal-title":"Semin Arthritis Rheum"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/acr.20162","volume":"62","author":"Coates L.C.","year":"2010","unstructured":"Coates L.C.; Cook R.; Lee K.A.; Chandran V.; Gladman D.D.; Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res (Hoboken)  2010,62(7),970-976","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s40265-018-0994-3","volume":"78","author":"Ye W.","year":"2018","unstructured":"Ye W.; Tucker L.J.; Coates L.C.; Tapering and discontinuation of biologics in patients with psoriatic arthritis with low disease activity. Drugs  2018,78(16),1705-1715","journal-title":"Drugs"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/acr.22529","volume":"67","author":"Haddad A.","year":"2015","unstructured":"Haddad A.; Thavaneswaran A.; Ruiz-Arruza I.; Pellett F.; Chandran V.; Cook R.J.; Gladman D.D.; Minimal disease activity and anti-tumor necrosis factor therapy in psoriatic arthritis. Arthritis Care Res (Hoboken)  2015,67(6),842-847","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1136\/annrheumdis-2013-204229","volume":"74","author":"Araujo e.g.","year":"2015","unstructured":"Araujo e.g.; Finzel S.; Englbrecht M.; Schreiber D.A.; Faustini F.; Hueber A.; Nas K.; Rech J.; Schett G.; High incidence of disease recurrence after discontinuation of disease-modifying antirheumatic drug treatment in patients with psoriatic arthritis in remission. Ann Rheum Dis  2015,74(4),655-660","journal-title":"Ann Rheum Dis"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1002\/art.41716","volume":"73","author":"Coates L.C.","year":"2021","unstructured":"Coates L.C.; Pillai S.G.; Tahir H.; Valter I.; Chandran V.; Kameda H.; Okada M.; Kerr L.; Alves D.; Park S.Y.; Adams D.H.; Gallo G.; Hufford M.M.; Hojnik M.; Mease P.J.; Kavanaugh A.; Withdrawing ixekizumab in patients with psoriatic arthritis who achieved minimal disease activity: results from a randomized, double-blind withdrawal study. Arthritis Rheumatol  2021,73(9),1663-1672","journal-title":"Arthritis Rheumatol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"e000395","DOI":"10.1136\/rmdopen-2016-000395","volume":"3","author":"Huynh D.H.","year":"2017","unstructured":"Huynh D.H.; Boyd T.A.; Etzel C.J.; Cox V.; Kremer J.; Mease P.; Kavanaugh A.; Persistence of low disease activity after tumour necrosis factor inhibitor (TNFi) discontinuation in patients with psoriatic arthritis. RMD Open  2017,3(1),e000395","journal-title":"RMD Open"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1136\/annrheumdis-2022-222260","volume":"81","author":"Michielsens C.A.J.","year":"2022","unstructured":"Michielsens C.A.J.; den Broeder N.; van den Hoogen F.H.J.; Mahler E.A.M.; Teerenstra S.; van der Heijde D.; Verhoef L.M.; den Broeder A.A.; Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial. Ann Rheum Dis  2022,81(10),1392-1399","journal-title":"Ann Rheum Dis"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","volume":"80","author":"Nagy G.","year":"2021","unstructured":"Nagy G.; Roodenrijs N.M.T.; Welsing P.M.J.; Kedves M.; Hamar A.; van der Goes M.C.; Kent A.; Bakkers M.; Blaas E.; Senolt L.; Szekanecz Z.; Choy E.; Dougados M.; Jacobs J.W.G.; Geenen R.; Bijlsma H.W.J.; Zink A.; Aletaha D.; Schoneveld L.; van Riel P.; Gutermann L.; Prior Y.; Nikiphorou E.; Ferraccioli G.; Schett G.; Hyrich K.L.; Mueller-Ladner U.; Buch M.H.; McInnes I.B.; van der Heijde D.; van Laar J.M.; Eular definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis  2021,80(1),31-35","journal-title":"Ann Rheum Dis"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1111\/bjd.15152","volume":"176","author":"Griffiths C.E.M.","year":"2017","unstructured":"Griffiths C.E.M.; Tha&#xE7;i D.; Gerdes S.; Arenberger P.; Pulka G.; Kingo K.; Weglowska J.; Hattebuhr N.; Poetzl J.; Woehling H.; Wuerth G.; Afonso M.; The egality study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol  2017,176(4),928-938","journal-title":"Br J Dermatol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.jaad.2016.12.014","volume":"76","author":"Papp K.","year":"2017","unstructured":"Papp K.; Bachelez H.; Costanzo A.; Foley P.; Gooderham M.; Kaur P.; Narbutt J.; Philipp S.; Spelman L.; Weglowska J.; Zhang N.; Strober B.; Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study. J Am Acad Dermatol  2017,76(6),1093-1102","journal-title":"J Am Acad Dermatol"}],"container-title":["Current Rheumatology Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115733971339350240830104424","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/237853\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115733971339350240830104424","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T04:09:34Z","timestamp":1763611774000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/237853\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":91,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115733971339350240830104424","relation":{},"ISSN":["1573-3971"],"issn-type":[{"value":"1573-3971","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-07-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}